JAG1
Overview
JAG1 (Jagged canonical Notch ligand 1) encodes a Notch pathway ligand. In oral squamous cell carcinoma (OSCC), copy gains of JAG1 have been identified alongside JAG2 gains; these ligand gains may either inhibit NOTCH1 through cis-inhibition or activate it, and are observed in the context where NOTCH1 functions as a tumor suppressor in OSCC.
Alterations observed in the corpus
- Copy gain observed in OSCC; Notch ligand gains may inhibit NOTCH1 via cis-inhibition or activate it, consistent with the tumor-suppressive role inferred for NOTCH1 in OSCC PMID:23619168
- JAG1 part of NOTCH-pathway alterations (NOTCH1–4, JAG1/JAG2, MAML1–3) totalling 31% of cases in a 109-case PDA WES cohort; amplification/mutation patterns nominate γ-secretase inhibitor MK0752 as a candidate therapy PMID:25855536
- JAG1 and JAG2 identified as Notch ligands among top MYB-target transcription regulators in adenoid cystic carcinoma (ACC); MYB drives Notch signaling through direct transcriptional activation of Notch ligands in low-grade ACC (n=20 WGS tumors) PMID:26829750
Cancer types (linked)
- OSCC (Oral Squamous Cell Carcinoma): copy number gain; co-occurs with JAG2 gains; mechanistic interpretation (cis-inhibition vs. activation of NOTCH1) is uncertain PMID:23619168
Co-occurrence and mutual exclusivity
- Co-gained with JAG2 in OSCC; both are Notch pathway ligands; NOTCH1 is mutated in 9% of OSCC and functions as a tumor suppressor PMID:23619168
Therapeutic relevance
- No direct therapeutic targeting reported; Notch pathway context in OSCC under investigation PMID:23619168
Open questions
- Mechanistic role of JAG1 copy gain in OSCC is ambiguous: whether it promotes cis-inhibition of NOTCH1 (tumor-suppressive) or activates Notch signaling (oncogenic) is unresolved PMID:23619168
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25855536
This page was processed by crosslinker on 2026-05-14. - PMID:26829750
This page was processed by wiki-cli on 2026-05-14.